Ocular Inflammatory Complications of Treatment for Metastatic Melanoma

Abstract

ABSTRACT Purpose To characterize various ocular inflammatory complications arising from metastatic cutaneous melanoma therapies and their management. Methods Retrospective case series of patients who were referred to a tertiary uveitis practice for ophthalmic exam All patients received targeted metastatic cutaneous melanoma treatment, including BRAF/MEK inhibitors and various immunotherapies. Results 109 patients were identified, with 43 (39.4%) having 65 definitive instances of OIAE. Sixteen different OIAE were identified. Ipilimumab monotherapy and ipilimumab/nivolumab combination therapy were most commonly associated. Anterior uveitis was the most common OIAE (18/65, 27.7%). Thirty patients (69.8%) were managed with observation or topical steroid therapy. Only 4 patients required further therapies for OIAE, with one patient not attaining resolution. Conclusions and Relevance While a broad range of OIAE was identified, most were not vision-threatening and did not require discontinuation of the associated therapy.